Latent Tuberculosis Clinical Trial
Official title:
Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB
Center for Disease Control (CDC) data reveal that after years of sustained decrease, the incidence of active tuberculosis (TB) disease in the US has plateaued. Most of the cases occur when Mycobacterium tuberculosis (Mtb) reactivates replication in people who have latent tuberculosis infection (LTBI). Only 5 to 10% of subjects with LTBI develop active TB Infection over their lifetime. Current US guidelines recommend treating everyone with LTBI to stop progression to active TB. As treatment is long, only about 45-55% of patients finish treatment overall, regardless of whether the patients are at high (>10%) or low lifetime risk of reactivation. The investigator's study aims to test the efficacy of a combined approach of first determining subjects at high risk of reactivation and then treating them with a CDC approved once a week treatment regimen, directly observed by a nurse over video (video-based Directly Observed Therapy, vDOT). Ensuring treatment of the high-risk group will eventually decrease the community active TB burden.
Tuberculosis (TB) in the US: Tuberculosis (TB), caused by the bacterium Mycobacterium
tuberculosis (Mtb), is a leading cause of mortality, killing more than a million people
worldwide^1. In the United States an important recent trend has been the plateauing of the
active TB disease incidence at 3.0 cases per 100,000 persons^2. Current US TB control
guidelines recommend treating all subjects with LTBI to prevent progression to active TB.
However, treatment is given with the antibiotic Isoniazid (INH) for 6-9 months, Rifampin and
Rifabutin for 4 months or INH with Rifapentine for 3 months and as subjects with LTBI are
asymptomatic, treatment default rates are understandably high (>10% on average)^3-5. It is
well known that a subset of patients with LTBI have higher risk of progression to active TB.
Because of the high treatment default rate, a number of these "high risk" subjects receive
incomplete or no preventive therapy and contribute to the incidence of active TB cases in the
US. Currently, there are no strategies being implemented to identify those at highest risk
and consequently treatment approaches follow the "one size fits all" paradigm. In the
investigators preliminary study done at the Saint Louis University (SLU) Infectious Diseases
Clinic, the investigators used an online risk calculator (TSTin3D.com)^6 to retrospectively
determine the cumulative lifetime risk of progression to active TB for adults receiving
treatment for latent TB. The investigators found that current practice leads to equal rates
of treatment completion i.e. 57% in the high risk for active TB disease (TBhi) group (>10%
cumulative risk of progression based on medical risk factors) compared to 59% for those at
lowest risk (TBlow, <10% cumulative risk of progression). It is not standard of care to use a
scoring system like the TSTin3d.com to assess the risk. There are certain risk factors like
having HIV or being on immunosuppression that physicians ask about but most physicians do not
do a quantitative risk assessment. Treatment choices are usually based on convenience and
concern for side effects but the most common regimen is daily INH for 6-9 months.
This data implies that the current "treat everyone and hope that therapy is completed"
approach leads to a significant number of people in the TBhi group remaining untreated and at
high risk of progression to active TB. A recent advance has been a CDC approved regimen using
Isoniazid (INH) and Rifapentine given weekly as directly observed therapy (DOT) for 12 weeks
(known as the 3HP regimen). This regimen has shown lower toxicity, better adherence and
equivalent efficacy^7-12. INH + Rifapentine (3HP) is not currently used widely as DOT is
resource intensive. The investigators hypothesize that if providers use the calculator
(TSTin3d.com) to firstly determine risk and then select the once weekly DOT for the TBhi
group (12 doses total); the investigators can ensure that the TBhi group completes treatment.
Complete treatment of the TBhi group will have the highest impact in decreasing the community
burden of TB disease. The investigators propose the first US study to prospectively test the
efficacy of an approach which 1) defines the TBhi group using TSTin3d.com and 2) ensures
treatment completion in the TBhi group with weekly with video-based DOT (vDOT) with 3HP. Most
patients nowadays have access to a smartphone with video capabilities. A HIPAA approved video
application (Zoom) is already available through the Missouri Telehealth Network and can be
used by the patient to interface with the TB clinic nurse over a smartphone. The
investigators approach removes the need for the patients in the TBhi group to be physically
present in the TB clinic. All patients identified in the TBhi group can thus be safely
provided vDOT. The investigators pilot study has important implications for improving care
and patient treatment outcomes as it will identify the "high risk" subjects with latent TB
using tstin3d.com (Table 1), [a validated online calculator that combines TST or interferon
Gamma Release Assay (IGRA) screening results with clinical information obtained from the
patient, to generate an individual's cumulative risk of developing active TB disease, up to
age 80^11]. The investigators will then ensure that patients complete therapy under direct
observation by a nurse using video based Directly Observed Therapy (vDOT). vDOT also
eliminates the need for the patient to physically visit the clinic. All patients need is
access to a smartphone with video capabilities. HIPAA approved video based applications are
already available for vDOT and has already been implemented successfully.^13
All of the drug options listed are standard of care currently in the US. It is currently not
standard of care to use a scoring system like tstin3d.com to assess risk. There are certain
risk factors like having HIV or being on immunosuppression that physicians routinely ask
about but most physicians do not do a quantitative risk assessment. Treatment choices are
usually based on convenience and concern for side effects but the most common regimen is
daily INH for 6 months or 9 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
Not yet recruiting |
NCT04428294 -
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
|
Phase 4 | |
Completed |
NCT02276755 -
Vitamin D Supplementation in TB Prevention
|
Phase 3 | |
Withdrawn |
NCT03498534 -
Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
|
Phase 4 | |
Active, not recruiting |
NCT03988933 -
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
|
Phase 2 | |
Recruiting |
NCT06022146 -
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
|
Phase 3 | |
Active, not recruiting |
NCT04188041 -
Improving Rhode Island's Tuberculosis Preventive Services in Primary Care
|
N/A | |
Recruiting |
NCT03730181 -
Tuberculosis Clinical Trials Consortium Study 35
|
Phase 1/Phase 2 | |
Completed |
NCT01967134 -
Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
|
Phase 1 | |
Completed |
NCT00257907 -
Immune Response to Mycobacterium Tuberculosis Infection
|
||
Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
Active, not recruiting |
NCT04557176 -
TB Screening Improves Preventive Therapy Uptake
|
N/A | |
Completed |
NCT02119130 -
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
|
N/A | |
Not yet recruiting |
NCT06281834 -
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
|
Phase 1 | |
Not yet recruiting |
NCT02512484 -
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
|
N/A | |
Completed |
NCT00763295 -
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
|
N/A | |
Completed |
NCT01850043 -
The Epidemiology of TST Change in Korea
|
N/A | |
Completed |
NCT02090374 -
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
|
N/A | |
Completed |
NCT02073669 -
Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults
|
N/A | |
Completed |
NCT02880982 -
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
|
Phase 3 |